Corcept's earnings blowout and raised outlook lift the stock
Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.
This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.
New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.
It shows a second revenue source actually selling, a new fact that supports the bull case.
Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.
Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.
Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.
Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.